Ordering
Available Variants1 mg
CHA.48926-1mg
Price
€220.80
Available – Dispatch in 14 days
5 mg
CHA.48926-5mg
Price
€548.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
1 mg | CHA.48926-1mg | €220.80 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.48926-5mg | €548.00 |
≥98% (HPLC), selective PPARδ agonist, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C21H17F4NO3S2 |
|---|---|
| CAS Number | 317318-84-6 |
| Molecular Weight | 471.49 |
| UNSPSC Code | 12352200 |
| PubChem Substance ID | 24895123 |
| NACRES | NA.77 |
| MDL number | MFCD07369423 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, type N95 (US) |
Technical Overview & Applications Use-case context
GW0742, also known by its CAS number 317318-84-6, is a synthetic peroxisome proliferator-activated receptor delta (PPARδ) agonist. This compound has been extensively studied for its potential therapeutic benefits, particularly in the areas of metabolic disorders and cardiovascular health. GW0742 has been shown to exhibit high affinity and selectivity for PPARδ, leading to increased fatty acid oxidation and improved insulin sensitivity. Additionally, it has been found to have anti-inflammatory properties, which may contribute to its potential as a treatment for various diseases. The activation of PPARδ by GW0742 has also been linked to enhanced exercise performance and increased mitochondrial biogenesis, further highlighting its potential as a therapeutic agent. Overall, GW0742 is a promising compound that warrants further investigation into its therapeutic applications.
